Public Consultation on Prescribed Exceptions in Copyright Regulations 2021

22 APR 2024

Consultation Period:
22 April 2024 to 19 May 2024*

MinLaw and IPOS are seeking comments on situations in which users should be permitted to circumvent technological measures that control access to copyright works or protected performances (“access control measures”).

Background

Access control measures are technologies, devices, or components that are akin to digital locks; in the normal course of their operation, they effectively control access to copyright works and protected performances. Though the Copyright Act 2021 (“CA”) prohibits the circumvention of these access control measures, in limited situations, the CA also provides exceptions where users can circumvent them for legitimate uses. Some exceptions require regular reviews, and this set of exceptions is the focus of the public consultation.

Public consultation documents

The public consultation paper can be accessed below:

Providing feedback

Please provide your feedback by 19 May 2024*.

*Following feedback from the public, the consultation exercise will be extended. It will now close on 2 June 2024 instead. We invite all interested parties to provide responses by then.

Feedback may be submitted via the following channels:

Our feedback website:
http://go.gov.sg/prescribedexceptions-consult2024

Hard Copy via Post:
Intellectual Property Policy Division, Ministry of Law
100 High Street, #08-02,
The Treasury Singapore 179434

Email: MLAW_Consultation@mlaw.gov.sg

Please include your name, contact number, and email address in your submission, so that we may contact you for any clarifications or follow-up questions if necessary.

Confidentiality of feedback received

MinLaw and IPOS reserve the right to make public all or parts of any written submission and disclose the identity of the source. Commenting parties may request for confidentiality for any part of the submission that is believed to be proprietary, confidential or commercially sensitive. Any such information should be clearly marked and placed in a separate annex. If we grant confidential treatment, we will consider, but will not publicly disclose, the information. If we reject the request for confidential treatment, the information will be returned to the party that submitted it and will not be considered as part of this review. As far as possible, parties should limit any request for confidential treatment of information submitted. We will not accept any submission that requests confidential treatment of all, or a substantial part, of the submission.

Last updated on 14 May 2024